Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Torrent Pharma to...

    Torrent Pharma to acquire Glochem's Vizag-based API unit

    Written by savita thakur thakur Published On 2016-07-03T12:52:18+05:30  |  Updated On 3 July 2016 12:52 PM IST
    Torrent Pharma to acquire Glochems Vizag-based API unit

    New Delhi : Torrent Pharmaceuticals said it has inked a pact to acquire Glochem Industries' Vizag-based manufacturing facility along with some drug master files.


    The company has entered a binding agreement to acquire the Vizag API manufacturing unit of Hyderabad-based Glochem Industries along with a few drug master files (DMF) as a going concern on slump sale basis, Torrent Pharma said in a regulatory filing.


    "Acquisition of this site will further help in backward integration and scale up Torrent's manufacturing capacity to meet the growing demand from the international markets," Torrent Pharma Executive Director (Operations) Jinesh Shah said.


    A DMF is a confidential, detailed document submitted by active pharmaceutical ingredient (API) manufacturers to the US Food and Drug Administration (FDA). It contains the chemistry, manufacturing and controls of a drug component.


    Ahmedabad-based Torrent Pharma has five formulation manufacturing units, and with the latest acquisition it will have three API facilities for the regulated markets. The unit is approved by the USFDA and the European regulatory authorities. It is a multi product facility with a capacity to manufacture advanced intermediates and APIs.


    The facility has three blocks for advanced intermediate manufacturing and four blocks for API manufacturing. The plant also has capabilities for on site development, analytical method development, quality control laboratory and a pilot plant.

    acquireAcquisitionAPIDMFdrug master filesGlochemJinesh ShahTorrent PharmaUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok